Nanomedicine Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Nanomedicine stocks.

Nanomedicine Stocks Recent News

Date Stock Title
Oct 1 AZN AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
Oct 1 AZN AstraZeneca's Enhertu application accepted by FDA with priority review
Oct 1 AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
Oct 1 AZN 5 FDA decisions to watch in the fourth quarter
Sep 30 AZN AstraZeneca (AZN): A Strong Buy as FDA Approves Key Cancer Treatments and Revenue Surges
Sep 30 AZN Is AstraZeneca PLC (NASDAQ:AZN) The Top Global Stock To Buy Now?
Sep 29 AZN Is AstraZeneca PLC (AZN) the Best Cheap Growth Stock to Buy According to Analysts?
Sep 28 AZN 15 Unhealthiest Countries in Europe
Sep 27 AZN Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More
Sep 27 AZN The Zacks Analyst Blog Highlights Toyota Motor, AstraZeneca, Chubb, Air T and Preformed Line Products
Sep 27 AZN US’ first self-administered flu vaccine could increase accessibility and uptake
Sep 27 AZN ANGLE PLC (ANPCY) (Q2 2024) Earnings Call Transcript Highlights: Key Takeaways from the ...
Sep 27 AZN AstraZeneca’s Tagrisso gains FDA approval for stage III NSCLC
Sep 26 AZN Top Stock Reports for Toyota, AstraZeneca & Chubb
Sep 26 AZN AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy?
Sep 26 AZN AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC
Sep 26 CLNN IBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA Leadership
Sep 26 AZN AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
Sep 26 AZN AstraZeneca gets FDA expanded approval for Tagrisso
Sep 26 AZN Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
Nanomedicine

Nanomedicine is the medical application of nanotechnology. Nanomedicine ranges from the medical applications of nanomaterials and biological devices, to nanoelectronic biosensors, and even possible future applications of molecular nanotechnology such as biological machines. Current problems for nanomedicine involve understanding the issues related to toxicity and environmental impact of nanoscale materials (materials whose structure is on the scale of nanometers, i.e. billionths of a meter).Functionalities can be added to nanomaterials by interfacing them with biological molecules or structures. The size of nanomaterials is similar to that of most biological molecules and structures; therefore, nanomaterials can be useful for both in vivo and in vitro biomedical research and applications. Thus far, the integration of nanomaterials with biology has led to the development of diagnostic devices, contrast agents, analytical tools, physical therapy applications, and drug delivery vehicles.
Nanomedicine seeks to deliver a valuable set of research tools and clinically useful devices in the near future. The National Nanotechnology Initiative expects new commercial applications in the pharmaceutical industry that may include advanced drug delivery systems, new therapies, and in vivo imaging. Nanomedicine research is receiving funding from the US National Institutes of Health Common Fund program, supporting four nanomedicine development centers.Nanomedicine sales reached $16 billion in 2015, with a minimum of $3.8 billion in nanotechnology R&D being invested every year. Global funding for emerging nanotechnology increased by 45% per year in recent years, with product sales exceeding $1 trillion in 2013. As the nanomedicine industry continues to grow, it is expected to have a significant impact on the economy.

Browse All Tags